GlassScriptPhysician profile
Michael Young Joo
NPI 1316560840
$1,465.28
in general payments reported to CMS, 2019-2025
10 companies · $675 in 2025
The $675 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $430 · 2024: $361 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,215 · Consulting Fee: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,215.28 |
| Consulting Fee | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $543.76 | 2023-2025 | |
| Elucent Medical | $269.69 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $130.37 | 2023 | Tezspire |
| United Therapeutics Corporation | $126.33 | 2023-2024 | Tyvaso |
| Foundation Medicine, INC. | $124.22 | 2023 | |
| Ani Pharmaceuticals, INC. | $100.00 | 2024 | Purified Cortrophin Gel |
| Insmed, INC. | $57.89 | 2024-2025 | Arikayce |
| Mindray Ds USA, INC. | $48.21 | 2025 | Te7 Max, Te X |
| Pulmonx Corporation | $47.46 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Harmony Biosciences LLC | $17.35 | 2023 | Wakix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Joo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.